News Releases

Date Title and Summary Additional Formats
Toggle Summary Avid Bioservices Added to Russell 3000® Index and Russell 2000® Index
TUSTIN, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology
View HTML
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , June 06, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology
View HTML
Toggle Summary Avid Bioservices to Participate at BIO International Convention 2018
-- Corporate Booth to Include Virtual Tour of Myford Late-Stage Clinical and Commercial Biomanufacturing Facility Highlighting Immediately Available 2,000-Liter Scale Bioreactor Capacity -- -- Company’s Newly Appointed Director of Business Development for East Coast to Join Team at BIO 2018 --
View HTML
Toggle Summary Avid Bioservices Announces Appointment of Magnus Schroeder, Ph.D., as Vice President of Process Sciences
-- Addition of Senior Executive with Significant Process Science Experience Supports Company's Efforts to Expand and Enhance Process Development Capabilities -- TUSTIN, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development
View HTML
Toggle Summary Avid Bioservices Provides Update on Ongoing Expansion of Process Development Capabilities and Laboratory Infrastructure
E nhancements Support New Customer Acquisition Efforts, Highlighted by Recent Signing of Three New Process Development and Manufacturing Agreements TUSTIN, Calif. , April 24, 2018 (GLOBE NEWSWIRE) --   Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and
View HTML
Toggle Summary Avid Bioservices to Participate at INTERPHEX 2018
TUSTIN, Calif. , April 09, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices Receives Six 2018 CMO Leadership Awards
Company Honored for Quality, Reliability, Capabilities, Expertise, Compatibility, and Service in Contract Development and Manufacturing Industry
View HTML
Toggle Summary Avid Bioservices to Participate at Upcoming CDMO Industry Conferences
TUSTIN, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices Reports Financial Results for Third Quarter of Fiscal Year 2018 and Recent Developments
   Company Remains on Target for Full Year Revenue of $50.0 - $55.0 Million               Intensified Business Development Effort Results in New Customer Contract and Strengthened Backlog                        TUSTIN, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc.
View HTML
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , March 07, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Present at the 30th Annual ROTH Conference
TUSTIN, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018
TUSTIN, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer's Disease Candidate
TUSTIN, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices Announces Resignation of Chief Financial Officer
Search for Replacement has Commenced
View HTML
Toggle Summary Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
TUSTIN, Calif. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that Enzyvant, a subsidiary of
View HTML